Truist Securities Reiterates Buy Rating on Guardian Pharmacy Services
Truist Securities maintains its Buy rating on Guardian Pharmacy Services with a $47 price target, a 19.93% upside from the current price.
Key Points
- Truist Securities reiterated its Buy rating on Guardian Pharmacy Services, setting a $47 price target on June 17, 2026.
- Truist Securities's $47 price target implies 19.93% upside from Guardian Pharmacy Services, Inc.'s ($GRDN) current $39.19 share price.
- Guardian Pharmacy Services trades at $42.42 with a market cap of approximately $2.75 billion and a P/E ratio of 51.67.
- Peers like Driehaus Capital Management increased their holdings, while Silvercrest Asset Management reduced theirs.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Truist Securities has reiterated its Buy rating on Guardian Pharmacy Services, Inc. (NYSE:GRDN), maintaining a price target of $47. This update was made by analyst David Macdonald on June 17, 2026. The stock is currently trading at around $42.42 per share.
Other Institutional Activity in Guardian Pharmacy Services
In the institutional scene, Driehaus Capital Management LLC increased its stake in Guardian Pharmacy Services by 82,646 shares, ending with 589,121 shares valued at about $22.19 million. On the other hand, Silvercrest Asset Management Group LLC reduced its holdings by 397,635 shares, now holding 374,946 shares worth approximately $14.12 million. Peregrine Capital Management LLC also trimmed its position by 19,453 shares, leaving it with 201,603 shares valued at $7.59 million. Meanwhile, Legato Capital Management LLC initiated a new position with 58,890 shares valued at $2.22 million.
Guardian Pharmacy Services, Inc. Stock Up 5.7%
Shares of Guardian Pharmacy Services trade near $42.42. The company has a market cap of approximately $2.75 billion and a P/E ratio of 51.67, with a forward P/E of 31.95. The stock has a 52-week low of $19.30 and a high of $43.96, with a 50-day moving average of $38.44 and a 200-day moving average of $32.27. The company maintains a current ratio of 1.47 and a quick ratio of 1.1, with a debt-to-equity ratio of 17.72.
Recent Earnings
Guardian Pharmacy Services reported revenue of about $1.46 billion, reflecting a growth of 2.2%. The company's earnings per share (EPS) stand at $0.84, with a net margin of 3.65% and a return on equity (ROE) of 26.91%. The next earnings report is scheduled for August 10, 2026.
Analysts Set New Price Targets
On June 17, 2026, Truist Securities maintained its Buy rating on Guardian Pharmacy Services with a $47 price target. B of A Securities also maintained a Buy rating with the same target. Previously, Oppenheimer maintained a Buy rating with a $43 target on May 7, 2026. The consensus among analysts is a strong buy, with a mean target price of $44.17 based on six analyst opinions.
About Guardian Pharmacy Services
Guardian Pharmacy Services, Inc. is a healthcare company based in Atlanta, Georgia. It provides pharmacy services and technology-enabled solutions to long-term healthcare facilities across the United States. The company serves residents in various facilities, including assisted living and behavioral health centers, using its advanced clinical and drug dispensing capabilities. Founded in 2003, Guardian Pharmacy Services employs about 3,600 people and is led by CEO Fred P. Burke.
Bottom Line
Truist Securities' reiteration of a Buy rating signals confidence in Guardian Pharmacy Services' performance, setting a price target of $47. Investors keep an eye on such ratings for insights into potential stock movements. Remember, 13F filings and analyst updates reflect past decisions and may not indicate current positions.
Get Guardian Pharmacy Services, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GRDN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.